99mTc-EDDA/HYNIC-iPSMA Radiopharmaceutical for PSMA Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current SPECT imaging techniques using 99mTc radionuclides lack the high sensitivity required to effectively detect tumors overexpressing prostate-specific membrane antigen (PSMA) in prostate cancer, necessitating the development of more competitive molecules for improved detection.
Innovation Solution
A new radiopharmaceutical, 99mTc-EDDA/HYNIC-iPSMA, is developed, incorporating hydrazinonicotinamide (HYNIC) to increase lipophilicity and facilitate coupling to PSMA, combined with ethylenediaminediacetic acid for radiometal coordination, enhancing affinity and detection sensitivity via SPECT imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional 99mTc radiopharmaceuticals are used for SPECT imaging, then the imaging modality is widely available and cost-effective, but the detection sensitivity for PSMA-overexpressing tumors is insufficient
Solution Approach 1:
The patent combines multiple functional groups into a single radiopharmaceutical molecule: HYNIC for 99mTc chelation, EDDA for coordination sphere completion, and a lipophilic tail for PSMA hydrophobic site coupling. This merging of functions into one molecule achieves high detection sensitivity while maintaining compatibility with existing SPECT infrastructure
Solution Approach 2:
The radiopharmaceutical employs a composite molecular structure integrating inorganic-radiometal coordination chemistry (99mTc-HYNIC-EDDA complex) with organic lipophilic moieties that target PSMA. This composite approach enables the molecule to simultaneously achieve stable radiometal binding and high-affinity tumor targeting
2Reliability
If the lipophilicity of the radiopharmaceutical is increased to enhance coupling to PSMA hydrophobic sites, then the affinity for PSMA improves, but the stability and selectivity may be compromised
Solution Approach 1:
The radiopharmaceutical exhibits local quality differentiation: the HYNIC-EDDA portion provides hydrophilic, stable coordination chemistry for 99mTc binding, while the lipophilic tail provides hydrophobic interaction capability for PSMA coupling. This spatial separation of properties allows the molecule to achieve both stability and high affinity without compromising either characteristic
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 99mTc-EDDA/HYNIC-iPSMA radiopharmaceutical achieves high radiochemical purity and stability, with significant tumor capture and detection sensitivity, rivaling PET radionuclides in imaging PSMA-overexpressing lesions, demonstrating effective interaction with the hydrophobic active site of PSMA.
Implementation Method 1
hydrazinonicotinamide (HYNIC) as a chemical group critical in increasing the lipophilicity of the molecule for coupling to the hydrophobic sites of PSMA
Implementation Method 2
HYNIC as a chelating agent for the radiometal 99mTc
Implementation Method 3
ethylenediaminediacetic acid (EDDA) is used for completing the coordination sphere of the radiometal
Implementation Method 4
detects, with high affinity in vivo, the protein PSMA overexpressed in prostate cancer cells by SPECT molecular imaging techniques
Data Source
AI summary
The invention relates to a novel radiopharmaceutical that inhibits the prostate-specific membrane antigen (iPSMA), containing hydrazinonicotinamide (HYNIC) as a critical chemical group in increasing in the lipophilicity of the molecule for binding to the hydrophobic sites of the PSMA, combined with the conventional use of HYNIC as a chelating agent for radiometal 99mTc, in which the ethylenediaminetetraacetic acid (EDDA) is used to complete the coordination sphere of the radiometal. The novel radiopharmaceutical 99mTc-EDDA/HYNIC-iPSMA detects, with high affinity and sensitivity in vivo, the overexpressed PSMA protein in prostate cancer cells using SPECT molecular imaging techniques in nuclear medicine. The aim of the invention is to provide a novel specific radiopharmaceutical (radiopharmaceutical for molecular targets) for SPECT, with high sensitivity for the detection of tumours with overexpression of PSMA.